Repository logo
 

RAD54L2 counters TOP2-DNA adducts to promote genome stability.

Published version
Peer-reviewed

Repository DOI


Loading...
Thumbnail Image

Change log

Authors

D'Alessandro, Giuseppina  ORCID logo  https://orcid.org/0000-0001-5448-8652
Morales-Juarez, David A  ORCID logo  https://orcid.org/0000-0001-5370-5512
Serrano-Benitez, Almudena  ORCID logo  https://orcid.org/0000-0002-7263-6863

Abstract

The catalytic cycle of topoisomerase 2 (TOP2) enzymes proceeds via a transient DNA double-strand break (DSB) intermediate termed the TOP2 cleavage complex (TOP2cc), in which the TOP2 protein is covalently bound to DNA. Anticancer agents such as etoposide operate by stabilizing TOP2ccs, ultimately generating genotoxic TOP2-DNA protein cross-links that require processing and repair. Here, we identify RAD54 like 2 (RAD54L2) as a factor promoting TOP2cc resolution. We demonstrate that RAD54L2 acts through a novel mechanism together with zinc finger protein associated with tyrosyl-DNA phosphodiesterase 2 (TDP2) and TOP2 (ZATT/ZNF451) and independent of TDP2. Our work suggests a model wherein RAD54L2 recognizes sumoylated TOP2 and, using its ATPase activity, promotes TOP2cc resolution and prevents DSB exposure. These findings suggest RAD54L2-mediated TOP2cc resolution as a potential mechanism for cancer therapy resistance and highlight RAD54L2 as an attractive candidate for drug discovery.

Description

Journal Title

Sci Adv

Conference Name

Journal ISSN

2375-2548
2375-2548

Volume Title

9

Publisher

American Association for the Advancement of Science (AAAS)

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Cancer Research UK (DRCPGM\100005)
European Commission Horizon 2020 (H2020) ERC (855741)
Italian Association for Cancer Research (AIRC) (236950)
European Commission Horizon 2020 (H2020) Marie Sk?odowska-Curie actions (800924)
Wellcome Trust (206388/Z/17/Z)
Wellcome Trust (205253/Z/16/Z)
Cancer Research UK (C6946/A24843)
Cancer Research UK (C17918/A28870)
Wellcome Trust (203144/A/16/Z)